Hepatocyte-enriched LEAP2 in relation to heel bone density and osteoporosis-related phenotypes: an exploratory genetic and translational study
- 1Shenzhen Clinical College of Integrated Traditional Chinese and Western Medicine, Guangzhou University of Chinese Medicine
- 2Department of Spinal Orthopedics, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine
- 3Department of Geriatrics, Bao’an Central Hospital of Shenzhen
Abstract
Background: Unbiased evaluation of liver-derived factors may clarify endocrine links between hepatic metabolism and skeletal fragility; however, hepatic transcript abundance cannot be assumed to represent circulating protein or direct bone-cell signaling.
Methods: We screened 168 liver-secreted genes and 202 independent liver cis -eQTL signals across seven skeletal outcomes using outcome-wise false-discovery-rate control, Steiger direction checks, bilateral sum of single effects (SuSiE) fine-mapping, and a three-edge analysis of liver expression, circulating protein, and heel estimated bone mineral density (eBMD). LEAP2 was then examined in human liver cell-resolved, spatial and bulk datasets, public bone transcriptomes, an exploratory hospital serum cohort [30 osteoporosis (OP) and 30 nonosteoporosis (NOP) participants], and a 2 × 2 high-fat diet (HFD) × orchidectomy (Orx) mouse experiment.
Results: The confirmatory genetic screen was null. In the separately defined exploratory layer, LEAP2–heel eBMD was the sole pair meeting the prespecified bilateral SuSiE criteria (PP.H4 = 0.915327); heel eBMD is quantitative-ultrasound-derived rather than a dual-energy X-ray absorptiometry (DXA) outcome. The MR association remained significant after a post hoc Bonferroni correction across all 1,414 signal-outcome combinations (adjusted p = 1.39 × 10 ⁻¹⁴ ). Colocalization was prior-sensitive: PP.H4 was 0.8439 at p ₁₂ = 5 × 10 ⁻⁶ and 0.1903 under a deliberately conservative p ₁₂ = 1 × 10 ⁻⁵ /46 stress test, so no formal family-wise colocalization claim was made. The liver eQTL–circulating pQTL edge was analytically indeterminate because the pQTL model did not converge, and the complete genetic triangle was not supported. Hepatocytes dominated LEAP2 signal in all three cell-resolved datasets. Serum LEAP2 was lower in OP than NOP participants (median [IQR], 5.336 [3.780–6.083] vs. 8.153 [7.015–9.458] ng/mL; U = 854, p = 2.33 × 10 ⁻⁹ ), but age imbalance and unavailable metabolic covariates preclude an independent association claim. In mice, HFD and Orx were associated with adverse trabecular phenotypes and lower hepatic Leap2 and circulating LEAP2.
Conclusion: A null confirmatory screen and prior-sensitive exploratory colocalization nominate LEAP2 for further study but do not establish circulating mediation, direct bone-cell GHSR signaling, diagnostic utility, or a causal effect on bone.
Related
- Osteoimmunology and bone microenvironment remodeling in osteoporosis: mechanisms and translational perspectives
- Sepsis-associated endothelial dysfunction: clinical phenotypes, biomarkers, bedside evidence, and translational implications
- A mechanistic quantitative systems pharmacology framework enriched by multiscale data enables model-informed translational development of mesenchymal stem cell therapy in lupus nephritis.
- Serum EV-enriched proteomics reveals host-response subtypes and molecular similarity to organ dysfunction phenotypes in sepsis.
- Vitamin A and D Status, Selected Genetic Variants, and Allergy-Related Phenotypes: An Exploratory Retrospective Study
BibTeX
@article{xia2026hepatocyteenriched,
title = {{Hepatocyte-enriched LEAP2 in relation to heel bone density and osteoporosis-related phenotypes: an exploratory genetic and translational study}},
author = {Zhicong Xia and Guowen Bai and Xintian Zhang and Yueping Cai and Hongbo Wang and Xiaosheng Lin},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1959499},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1959499/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Hepatocyte-enriched LEAP2 in relation to heel bone density and osteoporosis-related phenotypes: an exploratory genetic and translational study
AU - Zhicong Xia
AU - Guowen Bai
AU - Xintian Zhang
AU - Yueping Cai
AU - Hongbo Wang
AU - Xiaosheng Lin
PY - 2026
DA - 2026/10/30
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1959499
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1959499/full
AB - Background: Unbiased evaluation of liver-derived factors may clarify endocrine links between hepatic metabolism and skeletal fragility; however, hepatic transcript abundance cannot be assumed to represent circulating protein or direct bone-cell signaling. Methods: We screened 168 liver-secreted genes and 202 independent liver cis -eQTL signals across seven skeletal outcomes using outcome-wise false-discovery-rate control, Steiger direction checks, bilateral sum of single effects (SuSiE) fine-mapping, and a three-edge analysis of liver expression, circulating protein, and heel estimated bone mineral density (eBMD). LEAP2 was then examined in human liver cell-resolved, spatial and bulk datasets, public bone transcriptomes, an exploratory hospital serum cohort [30 osteoporosis (OP) and 30 nonosteoporosis (NOP) participants], and a 2 × 2 high-fat diet (HFD) × orchidectomy (Orx) mouse experiment. Results: The confirmatory genetic screen was null. In the separately defined exploratory layer, LEAP2–heel eBMD was the sole pair meeting the prespecified bilateral SuSiE criteria (PP.H4 = 0.915327); heel eBMD is quantitative-ultrasound-derived rather than a dual-energy X-ray absorptiometry (DXA) outcome. The MR association remained significant after a post hoc Bonferroni correction across all 1,414 signal-outcome combinations (adjusted p = 1.39 × 10 ⁻¹⁴ ). Colocalization was prior-sensitive: PP.H4 was 0.8439 at p ₁₂ = 5 × 10 ⁻⁶ and 0.1903 under a deliberately conservative p ₁₂ = 1 × 10 ⁻⁵ /46 stress test, so no formal family-wise colocalization claim was made. The liver eQTL–circulating pQTL edge was analytically indeterminate because the pQTL model did not converge, and the complete genetic triangle was not supported. Hepatocytes dominated LEAP2 signal in all three cell-resolved datasets. Serum LEAP2 was lower in OP than NOP participants (median [IQR], 5.336 [3.780–6.083] vs. 8.153 [7.015–9.458] ng/mL; U = 854, p = 2.33 × 10 ⁻⁹ ), but age imbalance and unavailable metabolic covariates preclude an independent association claim. In mice, HFD and Orx were associated with adverse trabecular phenotypes and lower hepatic Leap2 and circulating LEAP2. Conclusion: A null confirmatory screen and prior-sensitive exploratory colocalization nominate LEAP2 for further study but do not establish circulating mediation, direct bone-cell GHSR signaling, diagnostic utility, or a causal effect on bone.
SN - 1664-2392
ER -